Dynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, ...

Dynavax Technologies Corp. (DVAX) on Thursday said that its experimental Shingles vaccine yielded positive results in an ...

Shares in Dynavax Technologies Corporation closed 5% higher Thursday after the presentation of positive top-line results from ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...

Dynavax Technologies (NASDAQ:DVAX) added ~7% in the premarket on Thursday after the company said that its experimental ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Shingrix, the new shingles vaccine, is over 90 percent effective in preventing the painful viral infection Julie Mazziotta is the Senior Sports Editor at PEOPLE, covering everything from the NFL ...

Shingrix's efficacy rate is more than 90%, according to GSK. Experts recommend anyone who wants Shingrix to get on the waitlist at a pharmacy, clinic or doctor's office.

Shingrix’s strong showing was mainly the result of a large order from a U.S. retail pharmacy chain, GSK chief commercial officer Luke Miels told investors during a separate call. After the ...

RELATED: GlaxoSmithKline's Shingrix zooms toward blockbuster status despite tight supply GSK makes the shots, which take 6 to 9 months to produce, at a plant in Belgium.